Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls

@article{Riddle2012PramipexoleAM,
  title={Pramipexole- and methamphetamine-induced reward-mediated behavior in a rodent model of Parkinson's disease and controls},
  author={Jennifer L. Riddle and Sandra L Rokosik and T. Celeste Napier},
  journal={Behavioural Brain Research},
  year={2012},
  volume={233},
  pages={15-23}
}
Pramipexole (PPX) is a dopamine agonist that is FDA-approved for treatment of motor dysfunction in Parkinson's disease and restless leg syndrome. In a subpopulation of treated patients, PPX can lead to impulsive-compulsive disorders including behavioral addictions and dopamine dysregulation syndrome, a phenomenon that mirrors drug addiction. Regardless of this clinical picture, the capacity of PPX to regulate reward-mediated behaviors remains unclear and has not been evaluated in an animal… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 90 references

) 15 – 23 study of L - dopa , bromocriptine and pramipexole in healthy subjects

J Micallef, M Rey, +5 authors O Blin
British Journal of Clinical Pharmacology • 2012

Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague - Dawley rats

F Chaperon, MH Thiébot
Pharmacology Biochemistry and Behavior • 2011

Similar Papers

Loading similar papers…